

STELARA (USTEKINUMAB) ORDERS

PATIENT INFORMATION		PRESCRIBER INFORMATION	
Patient Name: _____		Prescriber Name: _____	
Address: _____		NPI: _____	
City, State, Zip: _____		Address: _____	
Cell: _____	Email: _____	City, State, Zip: _____	
Height: _____ Weight: _____ kg	Last 4 of SSN: _____	Phone: _____	Fax: _____
DOB: _____			
Allergies: _____		Contact Person: _____	

REFERRAL STATUS	
☐ New Referral	First dose? ☐ Yes ☐ No - Date of last infusion: _____
☐ Dose or Frequency Change	Line type: ☐ PIV ☐ PICC ☐ Port ☐ Other
☐ Continuation Order	

DIAGNOSIS	
☐ Crohn's Disease ICD 10 Code _____	☐ Plaque Psoriasis ICD 10 Code _____
☐ Psoriatic Arthritis ICD 10 Code _____	☐ Ulcerative Colitis ICD 10 Code _____
☐ ICD-10 CODE: _____	

REQUIRED DOCUMENTATION	
- This signed order form by the provider - Patient demographics and insurance information - H&P, labs, tests, and progress notes supporting diagnosis	- Prior Therapies: _____ - TB Screening ☐ Positive ☐ Negative Date: _____ - Hepatitis Screening ☐ Positive ☐ Negative Date: _____

PRESCRIBING INFORMATION			
Medication	Dose/Strength	Directions	Quantity
Ustekinumab	☐ 130 mg/ 26 ml	Loading dose for Crohn's Disease and Ulcerative Colitis Dilute in 0.9% NS 250 ml (100 ml for pediatric patients 10-25kg) and infuse IV over 1 hour ☐ 260 mg (<55 kg) ☐ 390 mg (55-85 kg) ☐ 520 mg (>85 kg)	Qty: sufficient for weight-based doses
Specific Brand (optional): _____	☐ 45 mg/ 0.5 ml	☐ Inject subcutaneously at week 0,4, then every 12 weeks ☐ Inject subcutaneously at week 8 after IV loading dose, then every 8 weeks ☐ Inject subcutaneously every _____ weeks	Qty: sufficient for dose per month Refill: _____
	☐ 90 mg/ ml		

If no product is specified, an insurance-preferred biosimilar may be used.

PREMEDICATIONS (administer 30 minutes prior to infusion)	
☐ Acetaminophen: ☐ 650 mg PO ☐ 1000 mg PO ☐ Diphenhydramine: ☐ 25 mg PO ☐ 50 mg PO ☐ Lab Work every _____ ☐ CMP ☐ CBC w dif ☐ CRP ☐ Sed Rate ☐ _____	
PIV: Flush with 3-10 mL of 0.9% sodium chloride before and after the infusion PICC/Midline: Flush 10 mL 0.9% NS before/after, then 3 mL Heparin 10 units/mL final flush Port: Flush 10 mL 0.9% NS before/after, then 5 mL Heparin 100 units/mL final flush	RN to manage VAD per company protocol and administer ordered therapy per manufacturer guideline Post-Infusion: Use 50 ml 0.9% NS bag to flush residual priming volume

STELARA (USTEKINUMAB) ORDERS

--	--

EMERGENCY MEDICATION

Administer the following medications as needed for infusion-related reactions per company protocol:

Adults (>40 kg): Diphenhydramine 25–50 mg PO or IV slow push (2–5 min); Acetaminophen 325–650 mg PO; Methylprednisolone 125 mg IV slow push (≥5 min); Epinephrine 0.3 mg IM/SQ, may repeat ×1; 0.9% NS 500 mL IV over 30–60 min, may repeat ×1 for hypotension.

Pediatrics and Adults under (<40 kg): Diphenhydramine 25 mg PO or IV slow push (2–5 min); Acetaminophen 325 mg PO; Methylprednisolone 40 mg IV slow push (≥5 min); Epinephrine 0.15 mg (<30 kg) or 0.3 mg (>30 kg) IM/SQ, may repeat ×1; 0.9% NS 500 mL IV over 30–60 min, may repeat ×1 for hypotension.

Oxygen (AIC/AIS only): 1–6 L/min via NC or face mask; titrate to maintain SpO₂ 95–100%.

Prescriber Signature X: _____ X: _____

Product Substitution Permitted: _____ Date: _____ Dispense as Written: _____ Date: _____